Biocryst Pharmaceuticals (BCRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.79, -2.87% vs the prior close of $8.02.
- Volume 4.40M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BCRX dips 2.9% to $7.79, a 6-month low, 5 down days in a row. Closed at $7.79, -2.87% vs the prior close of $8.02. Day range $7.74–$8.02, opened at $7.96.
BCRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BCRX dips 2.9% to $7.79, a 6-month low, 5 down days in a row
- Closed at $7.79, -2.87% vs the prior close of $8.02. Day range $7.74–$8.02, opened at $7.96.
- Volume was 4.40M shares, 1.0x its 50-day average of 4.43M.
- Price is -13.5% vs its 50-day average ($9.00) and -10.6% vs its 200-day average ($8.71).
- 52-week range $6.23–$11.22; today's close sits at 31% of that range, 30.6% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — BCRX dips 0.4% to $8.02, 4 down days in a row
- Closed at $8.02, -0.37% vs the prior close of $8.05. Day range $7.95–$8.24, opened at $8.11.
- Volume was 4.50M shares, 1.0x its 50-day average of 4.46M.
- Price is -11.2% vs its 50-day average ($9.03) and -8.0% vs its 200-day average ($8.71).
- 52-week range $6.23–$11.22; today's close sits at 36% of that range, 28.5% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — BCRX ends flat (-0.2%) to $8.05, 3 down days in a row
- Closed at $8.05, -0.25% vs the prior close of $8.07. Day range $7.97–$8.18, opened at $8.02.
- Volume was 5.65M shares, 1.3x its 50-day average of 4.41M.
- Price is -11.1% vs its 50-day average ($9.05) and -7.6% vs its 200-day average ($8.71).
- 52-week range $6.00–$11.22; today's close sits at 39% of that range, 28.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BCRX slides 3.5% to $8.07
- Closed at $8.07, -3.47% vs the prior close of $8.36. Day range $8.06–$8.32, opened at $8.22.
- Volume was 3.04M shares, 0.7x its 50-day average of 4.41M.
- Price is -11.1% vs its 50-day average ($9.07) and -7.3% vs its 200-day average ($8.71).
- 52-week range $6.00–$11.22; today's close sits at 40% of that range, 28.1% below the 52-week high.
Oct 12, 2026 — BCRX dips 2.2% to $8.36
- Closed at $8.36, -2.22% vs the prior close of $8.55. Day range $8.24–$8.55, opened at $8.49.
- Volume was 3.47M shares, 0.8x its 50-day average of 4.40M.
- Price is -8.0% vs its 50-day average ($9.09) and -4.0% vs its 200-day average ($8.71).
- 52-week range $6.00–$11.22; today's close sits at 45% of that range, 25.5% below the 52-week high.
Oct 9, 2026 — BCRX jumps 3.1% to $8.55
- Closed at $8.55, +3.14% vs the prior close of $8.29. Day range $8.27–$8.60, opened at $8.27.
- Volume was 2.31M shares, 0.5x its 50-day average of 4.40M — lighter than usual.
- Price is -6.1% vs its 50-day average ($9.10) and -1.8% vs its 200-day average ($8.70).
- 52-week range $6.00–$11.22; today's close sits at 49% of that range, 23.8% below the 52-week high.
Oct 8, 2026 — BCRX dips 1.3% to $8.29
- Closed at $8.29, -1.31% vs the prior close of $8.40. Day range $8.13–$8.40, opened at $8.36.
- Volume was 5.12M shares, 1.2x its 50-day average of 4.34M.
- Price is -9.0% vs its 50-day average ($9.11) and -4.7% vs its 200-day average ($8.70).
- 52-week range $6.00–$11.22; today's close sits at 44% of that range, 26.1% below the 52-week high.
Oct 7, 2026 — BCRX jumps 5.7% to $8.40
- Closed at $8.40, +5.66% vs the prior close of $7.95. Day range $7.86–$8.43, opened at $7.91.
- Volume was 5.12M shares, 1.2x its 50-day average of 4.30M.
- Price is -8.1% vs its 50-day average ($9.14) and -3.4% vs its 200-day average ($8.69).
- 52-week range $6.00–$11.22; today's close sits at 46% of that range, 25.1% below the 52-week high.
Oct 6, 2026 — BCRX dips 1.9% to $7.95, a 6-month low
- Closed at $7.95, -1.85% vs the prior close of $8.10. Day range $7.87–$8.15, opened at $8.15.
- Volume was 3.94M shares, 0.9x its 50-day average of 4.30M.
- Price is -13.3% vs its 50-day average ($9.17) and -8.5% vs its 200-day average ($8.69).
- 52-week range $6.00–$11.22; today's close sits at 37% of that range, 29.1% below the 52-week high.
Oct 5, 2026 — BCRX dips 0.9% to $8.10, a 6-month low
- Closed at $8.10, -0.86% vs the prior close of $8.17. Day range $7.92–$8.25, opened at $8.17.
- Volume was 4.71M shares, 1.1x its 50-day average of 4.25M.
- Price is -11.9% vs its 50-day average ($9.20) and -6.7% vs its 200-day average ($8.68).
- 52-week range $6.00–$11.22; today's close sits at 40% of that range, 27.8% below the 52-week high.
Oct 2, 2026 — BCRX rises 0.6% to $8.17
- Closed at $8.17, +0.62% vs the prior close of $8.12. Day range $7.92–$8.20, opened at $8.12.
- Volume was 6.15M shares, 1.5x its 50-day average of 4.16M.
- Price is -11.4% vs its 50-day average ($9.22) and -5.9% vs its 200-day average ($8.68).
- 52-week range $6.00–$11.22; today's close sits at 42% of that range, 27.2% below the 52-week high.
BCRX latest news & SEC filings
Every SEC filing by or about BCRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: $78.39M (prior year $5.08M) (+1441.7% vs Jun 30, 2025)
- Diluted EPS: $0.30 (prior year $0.02) (+1400.0% vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 2.05 — Costs tied to exiting activities / restructuring.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade BCRX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.73% (largest 5.7%).
- Liquidity: about 4.88M shares (≈$38.03M) trade per day on average.
- 52-week position: $7.79 vs a range of $6.23–$11.22 (31% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Amy E Mckee sold 11,180 shares on May 18, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 29, 2026.
- Share count: 255.54M shares outstanding (Jul 31, 2026), +21.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BCRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.96 | 8.02 | 7.74 | 7.79 | 4.40M |
| Oct 15, 2026 | 8.11 | 8.24 | 7.95 | 8.02 | 4.50M |
| Oct 14, 2026 | 8.02 | 8.18 | 7.97 | 8.05 | 5.65M |
| Oct 13, 2026 | 8.22 | 8.32 | 8.06 | 8.07 | 3.04M |
| Oct 12, 2026 | 8.49 | 8.55 | 8.24 | 8.36 | 3.47M |
| Oct 9, 2026 | 8.27 | 8.60 | 8.27 | 8.55 | 2.31M |
| Oct 8, 2026 | 8.36 | 8.40 | 8.13 | 8.29 | 5.12M |
| Oct 7, 2026 | 7.91 | 8.43 | 7.86 | 8.40 | 5.12M |
| Oct 6, 2026 | 8.15 | 8.15 | 7.87 | 7.95 | 3.94M |
| Oct 5, 2026 | 8.17 | 8.25 | 7.92 | 8.10 | 4.71M |
| Oct 2, 2026 | 8.12 | 8.20 | 7.92 | 8.17 | 6.15M |
| Oct 1, 2026 | 8.30 | 8.38 | 8.07 | 8.12 | 6.87M |
| Sep 30, 2026 | 8.28 | 8.42 | 8.18 | 8.33 | 13.10M |
| Sep 29, 2026 | 8.42 | 8.50 | 8.22 | 8.27 | 5.01M |
| Sep 28, 2026 | 8.56 | 8.66 | 8.34 | 8.47 | 4.35M |
| Sep 25, 2026 | 8.52 | 8.63 | 8.40 | 8.59 | 3.67M |
| Sep 24, 2026 | 8.54 | 8.65 | 8.40 | 8.52 | 4.85M |
| Sep 23, 2026 | 8.75 | 8.86 | 8.46 | 8.57 | 4.47M |
| Sep 22, 2026 | 8.87 | 9.04 | 8.72 | 8.78 | 3.44M |
| Sep 21, 2026 | 8.75 | 8.85 | 8.58 | 8.76 | 3.46M |
About Biocryst Pharmaceuticals
Biocryst Pharmaceuticals (BCRX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in DURHAM, NC. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 882796.
BCRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Steven Frank | Director | Sep 2, 2026 |
| Steven K Galson | Director | Jun 15, 2026 |
| Theresa Heggie | Director | Jun 15, 2026 |
| Alan G Levin | Director | Jun 15, 2026 |
| Vincent Milano | Director | Sep 2, 2026 |
| Amy E Mckee | Director | Sep 2, 2026 |
| Jill C. Milne | Director | Sep 2, 2026 |
| Machelle Sanders | Director | Jun 15, 2026 |
| Jon P Stonehouse | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Alane P Barnes | Chief Legal Officer | May 15, 2026 |
| Ronald Dullinger | Chief Commercial Officer | Jan 9, 2026 |
| Charles K Gayer | President and CCO | Dec 23, 2025 |
| Babar Ghias | Chief Financial Officer | Dec 19, 2025 |
| Sandeep Menon | Chief R&D Officer | Apr 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 18, 2026 | Amy E Mckee | Sale | 11,180 | $8.97 |
| May 18, 2026 | Amy E Mckee | Sale | 11,180 | $8.97 |
| May 18, 2026 | Amy E Mckee | Sale | 11,180 | $8.97 |
| May 18, 2026 | Amy E Mckee | Sale | 11,180 | $8.97 |
| May 13, 2026 | Alane P Barnes | Sale | 62,500 | $9.54 |
| May 13, 2026 | Alane P Barnes | Sale | 62,500 | $9.54 |
| May 13, 2026 | Alane P Barnes | Sale | 62,500 | $9.54 |
| May 13, 2026 | Alane P Barnes | Sale | 62,500 | $9.54 |
| Mar 20, 2026 | Theresa Heggie | Sale | 49,933 | $10.11 |
| Mar 20, 2026 | Theresa Heggie | Sale | 49,933 | $10.11 |
| Mar 20, 2026 | Theresa Heggie | Sale | 49,933 | $10.11 |
| Mar 20, 2026 | Theresa Heggie | Sale | 49,933 | $10.11 |
| Mar 16, 2026 | Alane P Barnes | Sale | 150,000 | $9.15 |
| Mar 16, 2026 | Alane P Barnes | Sale | 150,000 | $9.15 |
| Mar 16, 2026 | Alane P Barnes | Sale | 150,000 | $9.15 |
BCRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $263.86M | 1.21 | $347.37M |
| Dec 31, 2024 | — | $-88.88M | -0.43 | $-52.02M |
| Dec 31, 2023 | — | $-226.54M | -1.18 | $-95.14M |
| Dec 31, 2022 | — | $-247.12M | -1.33 | $-161.85M |
| Dec 31, 2021 | — | $-184.06M | -1.03 | $-142.16M |
Latest balance sheet: total assets $557.85M, total liabilities $1.01B, cash $154.97M (as of Jun 30, 2026).
BCRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $9.07 |
| May 6, 2026 | 8-K Item 2.02 (results) | $8.83 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $7.90 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $7.09 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $6.86 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $6.42 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $8.73 |
| May 5, 2025 | 8-K Item 2.02 (results) | $11.03 |
| Feb 24, 2025 | 8-K Item 2.02 (results) | $8.29 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $7.67 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $7.35 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BCRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.